Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 30;110(4):390–399. doi: 10.1093/jnci/djx219

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press 2017. This work is written by US Government employees and is in the public domain in the US.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/about_us/legal/notices)

PMC Copyright notice

Figure 7. — Effects of the NF-κB inhibitor Tanespimycin/17-AAG on angiosarcoma progression in mice. A)Deleted in Liver Cancer 1 (DLC1), clusterin, and TNFAIP3/A20 proteins in the murine angiosarcoma cell line ISOS-1. B and C) Tanespimycin/17-AAG and Fasudil treatment of ISOS-1 tumors established in syngeneic mice. The individual data points reflect tumor weight in individual mice (n = 10 mice/group in experiment #1, B; n = 9 mice/group in experiment #2 (C)); the horizontal lines reflect median tumor weight/group. Statistical significance displayed in (B and C) is calculated by analysis of variance with Tukey HSD post hoc test. D) p-myosin light chain immunostaining in ISOS-1 tumor tissues from control and treated mice. E) Clusterin mRNA levels are statistically significantly higher in ISOS-1 tumor tissues from mice treated with Tanespimycin/17-AAG than in control and Fasudil only–treated mice (mean [SD]; n = 9 mice/group, P values from two-sided paired Student’s t test are shown). Scale bar = 50 μm. DLC1 = Deleted in Liver Cancer 1; CLU = clusterin; pMLC = p-myosin light chain.